Créquit P - Search Results

1

Mapping of Crowdsourcing in Health: Systematic Review.

Créquit P, Mansouri G, Benchoufi M, Vivot A, Ravaud P. Créquit P, et al. J Med Internet Res. 2018 May 15;20(5):e187. doi: 10.2196/jmir.9330. J Med Internet Res. 2018. PMID: 29764795 Free PMC article.

2

Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.

Vivot A, Li J, Zeitoun JD, Mourah S, Crequit P, Ravaud P, Porcher R. Vivot A, et al. Among authors: crequit p. Genet Med. 2016 Aug;18(8):796-805. doi: 10.1038/gim.2015.165. Epub 2015 Dec 17. Genet Med. 2016. PMID: 26681315 Free article.

3

Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor.

Créquit P, Trinquart L, Ravaud P. Créquit P, et al. BMJ Open. 2016 Aug 3;6(8):e011841. doi: 10.1136/bmjopen-2016-011841. BMJ Open. 2016. PMID: 27489157 Free PMC article.

4

Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.

Vivot A, Jacot J, Zeitoun JD, Ravaud P, Crequit P, Porcher R. Vivot A, et al. Among authors: crequit p. Ann Oncol. 2017 May 1;28(5):1111-1116. doi: 10.1093/annonc/mdx053. Ann Oncol. 2017. PMID: 28453694 Free article.

5

Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis.

Créquit P, Chaimani A, Yavchitz A, Attiche N, Cadranel J, Trinquart L, Ravaud P. Créquit P, et al. BMC Med. 2017 Oct 30;15(1):193. doi: 10.1186/s12916-017-0954-x. BMC Med. 2017. PMID: 29082855 Free PMC article. Review.

6

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework.

Vivot A, Créquit P, Porcher R. Vivot A, et al. Among authors: crequit p. JAMA Oncol. 2018 Oct 1;4(10):1437-1438. doi: 10.1001/jamaoncol.2018.3289. JAMA Oncol. 2018. PMID: 30128475 No abstract available.

7

Living network meta-analysis was feasible when considering the pace of evidence generation.

Créquit P, Martin-Montoya T, Attiche N, Trinquart L, Vivot A, Ravaud P. Créquit P, et al. J Clin Epidemiol. 2019 Apr;108:10-16. doi: 10.1016/j.jclinepi.2018.12.008. Epub 2018 Dec 12. J Clin Epidemiol. 2019. PMID: 30552957

8

Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors.

Vivot A, Créquit P, Porcher R. Vivot A, et al. Among authors: crequit p. J Natl Cancer Inst. 2019 May 1;111(5):519-521. doi: 10.1093/jnci/djy211. J Natl Cancer Inst. 2019. PMID: 30615127 Free article.

9

Future of evidence ecosystem series: 2. current opportunities and need for better tools and methods.

Créquit P, Boutron I, Meerpohl J, Williams HC, Craig J, Ravaud P. Créquit P, et al. J Clin Epidemiol. 2020 Jul;123:143-152. doi: 10.1016/j.jclinepi.2020.01.023. Epub 2020 Mar 4. J Clin Epidemiol. 2020. PMID: 32145369

10

Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer.

Créquit P, Trinquart L, Yavchitz A, Ravaud P. Créquit P, et al. BMC Med. 2016 Jan 20;14:8. doi: 10.1186/s12916-016-0555-0. BMC Med. 2016. PMID: 26792360 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters